The European Medicines Agency has recommended granting pan-EU marketing authorization to 17 new drugs, including five that were granted orphan status during their development.
Andembry, Beyonttra, Rytelo Among 17 New Products To Receive EMA Backing
The European Medicines Agency has recommended several new products for pan-EU approval, including CSL Behring’s drug for hereditary angioedema and BridgeBio’s treatment for transthyretin amyloidosis in cardiomyopathy patients.
